Skip to main content
峆一药业 logo

峆一药业 — Investor Relations & Filings

Ticker · 920478 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2024-08-27 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920478

About 峆一药业

http://www.heryipharma.com/

Anhui Heyi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company focuses on providing high-quality chemical products for various therapeutic areas, including cardiovascular, central nervous system, and anti-infective treatments. With a strong emphasis on technological innovation and quality control, it operates advanced manufacturing facilities that adhere to international standards. Its product portfolio includes key intermediates for widely used medications, supporting both domestic and global pharmaceutical supply chains. The company leverages its expertise in complex chemical synthesis to offer customized solutions and reliable supply to its partners in the life sciences sector.

Recent filings

Filing Released Lang Actions
募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "专项报告" (special report) on the status of funds raised (募集资金存放与实际使用情况的专项报告) by 安徽峆一药业股份有限公司. It details the issuance of shares, the amount of funds raised, the management and use of these funds, including investment in projects, purchase of financial products, and compliance with regulatory requirements. The document does not contain full financial statements or comprehensive financial performance data typical of annual or interim reports. It is a detailed update on the use and management of capital raised through share issuance, which fits the definition of a Capital/Financing Update (CAP). The document length is under 5,000 characters, but it is substantive and not merely an announcement of a report publication. Therefore, it is classified as a Capital/Financing Update (CAP).
2024-08-27 Chinese
第四届董事会第十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 19th meeting of the 4th Board of Directors of Anhui Xuyi Pharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of two proposals: the 2024 semi-annual report and a special report on the use of raised funds. The document references the actual reports being disclosed on the Beijing Stock Exchange website with specific announcement numbers, indicating that this document itself is not the report but an announcement of the board meeting resolutions related to these reports. The document is relatively short (1361 characters) and serves as a meeting resolution announcement rather than containing substantive financial data or the full report. Therefore, it fits best under Board/Management Information (MANG) as it announces board meeting decisions and approvals.
2024-08-27 Chinese
2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告 2024" which translates to "2024 Half-Year Report" or "Interim Report". It contains detailed financial data including income, profit, assets, liabilities, cash flow, and operational details for the period January 1, 2024 to June 30, 2024. The document includes comprehensive financial statements, management discussion of business operations, risk factors, and other substantive financial and operational information. It explicitly states it is a half-year report and is unaudited. The length is about 15,000 characters, indicating a full report rather than a brief announcement. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive analysis. Therefore, the document should be classified as IR. H1 2024
2024-08-27 Chinese
第四届监事会第十八次会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Anhui Xuyi Pharmaceutical Co., Ltd. It details the meeting date, attendance, and voting results on specific agenda items. The agenda items include approval of the company's 2024 semi-annual report and a special report on the use of raised funds, both of which are referenced as being disclosed elsewhere on the Beijing Stock Exchange website. The document itself does not contain the actual semi-annual report or financial data but rather announces the resolutions passed in the Supervisory Board meeting. The document length is short (1022 characters) and it primarily serves as an announcement of meeting resolutions and voting results. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-08-27 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "半年度报告摘要" which translates to "Half-Year Report Summary" for the year 2024. It contains detailed financial data such as total assets, net profit, earnings per share, and other financial metrics for the reporting period. It also includes company business descriptions, shareholder information, and notes on asset pledges and restrictions. The document explicitly states it is a summary of the half-year report and references the full half-year report on the stock exchange website. The length is over 5,000 characters and contains substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-27 Chinese
关于签署募集资金四方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the approval by the China Securities Regulatory Commission for a public offering of shares by Anhui company, detailing the number of shares issued, the price, total funds raised, net proceeds after expenses, and the management and use of the raised funds. It includes references to regulatory approvals, fund custody, and agreements related to the management of the raised capital. There is no detailed financial statement or comprehensive report content, but rather a disclosure about the capital raising and fund management process. This fits the category of Capital/Financing Update (CAP), as it provides an update on the company's fundraising activities and capital structure changes.
2024-08-18 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.